Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling

Hypertension

Volumn 42, Issue 1, 2003, Pages 49-55

  Pu, Qian ^b   Neves, Mario Fritsch ^b   Virdis, Agostino ^b   Touyz, Rhian M ^b   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b NONE

Author keywords

Arteries; Endothelin; Extracellular matrix; Free radicals; Mineralocorticoids; Receptors; Resistance

Indexed keywords

5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; COLLAGEN; ENDOTHELIN A RECEPTOR ANTAGONIST; FIBRONECTIN; HYDRALAZINE; INTERCELLULAR ADHESION MOLECULE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SPIRONOLACTONE; 5 (DIMETHYLAMINO) N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; 5-(DIMETHYLAMINO)-N-(3,4-DIMETHYL-5-ISOXAZOLYL)-1-NAPHTHALENESULFONAMIDE; DANSYL CHLORIDE; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; VASODILATOR AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR SYSTEM; COLLAGEN SYNTHESIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ELECTROLYTE INTAKE; HYPERTENSION; INFUSION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; TUNICA MEDIA; VASCULAR ENDOTHELIUM; ANIMAL; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; CYTOLOGY; DRUG ANTAGONISM; EXTRACELLULAR MATRIX; HEART; HISTOLOGY; MESENTERIC ARTERY; METABOLISM; ORGAN SIZE; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; BLOOD PRESSURE; DANSYL COMPOUNDS; ENDOTHELINS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HEART; HYDRALAZINE; INTERCELLULAR ADHESION MOLECULE-1; MALE; MESENTERIC ARTERIES; NADPH OXIDASE; ORGAN SIZE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SPIRONOLACTONE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VASODILATOR AGENTS;

EID: 0038141826     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000078357.92682.EC     Document Type: Article

References (50)

1. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
2. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension. 2002;40:23-27.
3. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineral-ocorticoid blockade reduces vascular injury in stroke prone hypertensive rats. Hypertension. 1998;31:451-458.
4. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 1999;33:232-237.
5. Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension. 2001;37:1444-1449.
6. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
7. Yanagisawa M, Kurihara H, Kumura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
8. Schiffrin EL. Role of endothelin-1 in hypertension. Hypertension. 1999;34:876-881.
9. Li J-S, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
10. Schiffrin EL, Larivière R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension. 1995;25:769-773.
11. Cambiaggi C, Mencarelli M, Muscettola M, Grasso G. Gene expression of endothelin-1 (ET-1) and release of mature peptide by activated human neutrophils. Cytokine. 2001;14:230-233.
12. Tostes R, Touyz RM, He G, Chen X, Schiffrin EL. Contribution of ET-1 to renal AP-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin Sci. 2002;103:25S-30S.
13. Letizia C, De Toma G, Cerci S, Scuro L, De Ciocchis A, D'Ambrosio C, Massa R, Cavallaro A, Scavo D. Plasma endothelin-1 levels in patients with aldosterone-producing adenoma and pheochromocytoma. Clin Exp Hypertens. 1996;18:921-931.
14. Scholz H, Krämer BK, Hamann M, Götz KH, Kurtz A. Effects of endothelins on renin secretion from rat kidneys. Acta Physiol Scand. 1995;155:173-182.
15. Matsumura Y, Hisaki K, Ohyama T, Hayashi K, Morimoto S. Effects of endothelin on renal function and renin secretion in anesthetized rats. Eur J Pharmacol. 1989;166:577-580.
16. Cozza EN, Gomez-Sanchez CE. Mechanisms of ET-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol. 1993;265:E179-E183.
17. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res. 1999;43:300-307.
18. Kahler J, Mendel S, Weckmuller J, Orzechowski HD, Mittmann C, Koster R, Paul M, Meinertz T, Munzel T. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol. 2000;32:1429-1437.
19. Bradbury RH, Bath C, Butlin RJ, Dennis M, Heys C, Hunt SJ, James R, Mortlock AA, Sumner NF, Tang EK, Telford B, Whiting E, Wilson C. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-Npyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides. J Med Chem. 1997;40:996-1004.
20. Sharifi AM, Schiffrin EL. Endothelin receptors mediating vasoconstriction in rat pressurized small arteries. Can J Physiol Pharmacol. 1996;74:934-939.
21. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension. 2001;38:606-611.
22. Pu Q, Touyz RM, Schiffrin EL. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens. 2002;20:899-907.
23. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens. 1991;4:303-308.
24. Schisterman EF, Faraggi D, Browne R, Freudenheim J, Dorn J, Muti P, Armstrong D, Reiser B, Trevisan M. TBARS and cardiovascular disease in a population-based sample. J Cardiovasc Risk. 2001;8:219-225.
25. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993;21:294-300.
26. Larivière R, Deng LY, Day R, Sventek P, Thibault G, Schiffrin EL. Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell Cardiol. 1995;27:2123-2131.
27. Deng LY, Day R, Schiffrin EL. Localization of sites of enhanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats. J Am Soc Nephrol. 1996;7:1158-1164.
28. Schiffrin EL, Larivière R, Li JS, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: Correlation with vascular structure. J Vasc Res. 1996;33:235-248.
29. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens. 2002;15:164-169.
30. Intengan HD, He G, Schiffrin EL. Effect of V1 vasopressin antagonism on small artery structure and vascular expression of preproendothelin-1 in DOCA-salt hypertensive rats. Hypertension. 1998;32:770-777.
31. Intengan HD, Park J-B, Schiffrin EL. Blood pressure, resistance artery structure and mechanics in DOCA-salt-treated vasopressin-deficient Brattleboro rats: rote of endothelin. Hypertension. 1999;34:907-913.
32. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;289:24316-24320.
33. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res. 1992;71:503-510.
34. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
35. 2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int. 1999;56:471-478.
36. Haas JA, Kreiger JD, Bolterman R, Juncos LA, Romero JC. Low-dose angiotensin II increases free isoprostane levels in plasma. Hypertension. 1999;34:983-986.
37. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension. 1998;32:59-64.
38. Münzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest. 1996;6:98:1465-1470.
39. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107-1111.
40. Raij L. Hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension. 2001;37:767-773.
41. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, Giulini SM, Agabiti-Rosei E. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension. 1996;28:785-790.
42. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice: role of endothelin. J Clin Invest. 1998;101:2780-2789.
43. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763-771.
44. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
45. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155-161.
46. Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension. 1995;25:495-500.
47. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol. 1996;271:H88-H93.
48. Rossi GP, Cavallin M, Belloni AS, Mazzocchi G, Nussdorfer GG, Pessina AC, Sartore S. Aortic smooth muscle cell phenotypic modulation and fibrillar collagen deposition in angiotensin II-dependent hypertension. Cardiovasc Res. 2002;55:178-189.
49. Rossi GP, Sacchetto A, Rizzoni D, Bova S, Porteri E, Mazzocchi G, Belloni AS, Bahcelioglu M, Nussdorfer GG, Pessina AC. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler Thromb Vasc Biol. 2000;20:949-956.
50. Seccia TM, Belloni AS, Kreutz R, Paul M, Nussdorfer GG, Pessina AC, Rossi GP. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol. 2003;41:666-673.